title: Effect of Olmesartan on the Level of Oral Cancer Risk Factor PAI1.
abstract: To study if the angiotensin receptor blocker olmesartan reduces levels of plasminogen activator inhibitor 1 (PAI1), a risk factor for oral cancer, in a mouse model and therefore whether it could be used in the treatment of this malignancy.
  
  
  
  Twelve transgenic PAI1 mice aged 16-20 weeks were divided in two groups each containing six animals. One group was given olmesartan every day for 30 days in drinking water in an amount corresponding to their weight, 0.005 mg/g, while the second group did not receive any medication (control group). Blood samples were obtained from animals of both groups, before and after one month of olmesartan administration and plasma PAI1 levels were measured using enzyme-linked immunosorbent assay.
  
  
  
  In the olmesartan-treated group, a significant decrease of PAI1 level was found after 1 month of treatment (11.9±8.6 vs. 21.7±7.2 ng/ml, respectively; p=0.028). However, no statistically significant difference was observed in PAI1 levels between the olmesartan-treated and control groups after one month, (p=0.177).
  
  
  
  Olmesartan did not significantly affect PAI1 levels in this mouse model.
authors: Department of Oral and Maxillofacial Surgery, National and Kapodistrian University of Athens, Medical School, Attikon Hospital, Chaidari, Athens, Greece stvasil@med.uoa.gr.
authors: Stavros
authors: S
authors: Vassiliou
authors: Department of Oral and Maxillofacial Surgery, University of Vienna, Vienna, Austria.
authors: Emeka
authors: E
authors: Nkenke
authors: Department of Oral and Maxillofacial Surgery, National and Kapodistrian University of Athens, Medical School, Attikon Hospital, Chaidari, Athens, Greece.
authors: Nikos
authors: N
authors: Lefantzis
authors: Department of Nursing, Faculty of Human Movement and Quality of Life Sciences, University of Peloponnese, Sparta, Greece.|Department of Biopathology and Clinical Microbiology, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece.
authors: Anastasios
authors: A
authors: Ioannidis
authors: Department of Oral and Maxillofacial Surgery, National and Kapodistrian University of Athens, Medical School, Attikon Hospital, Chaidari, Athens, Greece.|First Department of Neurology, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece.
authors: Christos
authors: C
authors: Yapijakis
authors: Department of Biopathology and Clinical Microbiology, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece.
authors: Margarita
authors: M
authors: Zoga
authors: Department of Oral and Maxillofacial Surgery, National and Kapodistrian University of Athens, Medical School, Attikon Hospital, Chaidari, Athens, Greece.
authors: Veronica
authors: V
authors: Papakosta
authors: Department of Oral and Maxillofacial Surgery, National and Kapodistrian University of Athens, Medical School, Attikon Hospital, Chaidari, Athens, Greece.
authors: Spyridoula
authors: S
authors: Derka
authors: Department of Biopathology and Clinical Microbiology, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece.
authors: Chryssoula
authors: C
authors: Nikolaou
authors: Department of Oral and Maxillofacial Surgery, National and Kapodistrian University of Athens, Medical School, Attikon Hospital, Chaidari, Athens, Greece.
authors: Eleftherios
authors: E
authors: Vairaktaris
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009062:Mouth Neoplasms / Q000517:prevention & control*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D012307:Risk Factors; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D017395:Plasminogen Activator Inhibitor 1; D013777:Tetrazoles; C437965:olmesartan
keywords: PAI-1; olmesartan; oral cancer; transgenic mice